Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 2
2020 1
2022 3
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
Correction to: Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer.
Elsea D, Fan L, Mihai A, Moustaid FE, Simmons D, Monberg M, Muston D. Elsea D, et al. Among authors: mihai a. Pharmacoecon Open. 2022 Nov;6(6):899. doi: 10.1007/s41669-022-00372-0. Pharmacoecon Open. 2022. PMID: 36107308 Free PMC article. No abstract available.
Cost comparison of adverse event management among breast and ovarian cancer patients treated with poly (ADP-ribose) polymerase inhibitors: analysis based on phase 3 clinical trials.
Fan L, Zhang Y, Maguire P, Muston D, Monberg M, Earla JR, Mihai A, Gulati P. Fan L, et al. Among authors: mihai a. J Mark Access Health Policy. 2022 Jun 8;10(1):2078474. doi: 10.1080/20016689.2022.2078474. eCollection 2022. J Mark Access Health Policy. 2022. PMID: 35693379 Free PMC article.
Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer.
Elsea D, Fan L, Mihai A, Moustaid FE, Simmons D, Monberg M, Muston D. Elsea D, et al. Among authors: mihai a. Pharmacoecon Open. 2022 Nov;6(6):811-822. doi: 10.1007/s41669-022-00338-2. Epub 2022 Aug 29. Pharmacoecon Open. 2022. PMID: 36036344 Free PMC article.